Skip to content

Airway Complications After LMA in Children

The Frequency of Airway Complications After LMA Removal in Children: A Comparison of TIVA and Sevoflurane

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03553082
Enrollment
135
Registered
2018-06-12
Start date
2018-05-18
Completion date
2021-05-28
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Recovery

Brief summary

Background: The removal of Laryngeal Mask Airway (LMA) in children may be associated with respiratory adverse events. The incidence of these adverse events may be influenced by the type of anesthesia maintenance. It is not clear whether Total Intravenous Anesthesia (TIVA) with propofol is associated with a lower incidence of respiratory events upon removal of LMA as compared to maintenance with sevoflurane. Specific Aim: The primary aim of this study is to compare the prevalence of respiratory adverse events following LMA removal in patient receiving TIVA versus sevoflurane inhalational anesthesia in a pediatric population aged between 6 month and 6 years old. Secondary outcomes include quality of induction, maintenance and emergence from anesthesia between the 2 groups as evidenced by ease of LMA insertion, absence of bucking or movement during the procedure, time to LMA removal, and absence of emergence agitation. Methods: In this prospective randomized clinical trial, children will be enrolled in one of two groups: Group 1 will receive propofol for induction and maintenance of anesthesia, Group 2 will receive sevoflurane for induction and maintenance of anesthesia. In both groups patients will be mechanically ventilated. At the end of the procedure, LMAs will be removed when patients are fully awake as defined by the return of reflexes, eye opening, and purposeful movements. Significance: Data comparing the influence of TIVA and sevoflurane on the occurrence of respiratory adverse events after LMA removal are limited. Both techniques are standard of care at our institution. However, as per our clinical observations, we hypothesize that TIVA is superior to sevoflurane. This study will identify the technique that provides optimal anesthetic conditions and improved patient's safety.

Interventions

DRUGSevoflurane

Fentanyl 2 µg/kg for induction of anesthesia and sevoflurane 2% for maintenance

DRUGPropofol

Propofol 5-6 mg/kg and fentanyl 2 µg/kg for induction of anesthesia and propofol 250-300 µg/kg/min for maintenance

Sponsors

American University of Beirut Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
6 Months to 6 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 6 months to 6 years old 2. Patients undergoing short duration procedure ( ˂ 2 hours) (such as polysite removal, closed reduction, eye examination, excluding thoracic and abdominal surgery) 3. American Society of Anesthesiologists (ASA): I-III 4. Patients undergoing LMA general anesthesia. (NPO, short procedures, patient without known airway abnormalities). 5. Parental consent

Exclusion criteria

1. Age: more than 6 years old and less than 6 months 2. Patients having: Asthma, hyper reactive airway (Acute exacerbation) 3. Patients having recent respiratory tract infection within 2 weeks. 4. Patients with congenital heart disease 5. Patients not eligible for LMA (full stomach, hiatal hernia, known or predicted difficult airway, syndromic patient with facial or airway malformation, patient undergoing major abdominal or thoracic surgery) 6. Patients at high risk of aspiration 7. Anticipated difficult airway 8. Patient with neurologic disorders (children with known neurologic disorders: seizure, mental retardation, cerebral palsy) 9. Difficult LMA insertion (\> 3 attempts)

Design outcomes

Primary

MeasureTime frameDescription
Respiratory adverse outcomes2 hoursEncountered respiratory adverse outcomes such as cough

Secondary

MeasureTime frameDescription
Time to emergence2 hoursEmergence time defined as the time from discontinuation of the anesthetic agents until LMA removal.
LMA insertion characteristics2 hoursNumber of attempts and time taken to insertion, as well as adverse events encountered during insertion.
Quality of anesthesia2 hoursLack of movement, bucking, cough
Emergence agitation2 hours4 points scale: 1: calm, 2: not calm but easily consolable, 3: not easily calmed restless or moderately agitated, 4: combative, disoriented or excited.

Countries

Lebanon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026